Cryopreservation Cell Lines Market size was over USD 13.94 billion in 2024 and is projected to reach USD 152.41 billion by 2037, growing at around 20.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cryopreservation cell lines is assessed at USD 18.81 billion.
The major factor attributed to the market growth is the rising cases of infertility among the global population. As cryopreservation is used for the preservation of oocytes and embryos in the in-vitro fertilization (IVF) banking services for persevering the reproductive capacity of females, the increase in the prevalence of infertility is estimated to bring lucrative growth opportunities for the expansion of the global cryopreservation cell lines market. The data from the World Health Organization (WHO) stated that approximately 48 million couples and 186 million individuals of reproductive age have been suffering from infertility across the globe.
Through the process of cryopreservation, samples of tissues, cells, and organelles are stored at very low temperatures for preserving them from exterior environments. Apart from being used in in-vitro fertilization, the other growth factors for global cryopreservation cell lines are the high amount of investments being made in the research and development activities by major key players of the market for stem cells, and the recent escalation in government support for developing novel medical equipment. In addition, the rising geriatric population around the world, and rapid spreading of awareness about the advantages of cryopreservation cell lines, and the high focus on drug development are also estimated to create a positive outlook for market growth. Moreover, the surge in the focus of healthcare companies on developing novel products for preserving various cells and tissues for research and use in medical applications along with the growing use of advanced cryopreservation techniques by tissue engineering and biobanking facilities to maintain the functional characteristics of cells are also anticipated to drive the market growth during the forecast period.
Growth Drivers
Growing Government Support to Develop Cryopreservation Cell Lines – The government of different nations is focusing on developing advanced cryopreservation cell lines for preserving tissue cells and other human components for the conduction of tests and developing high-quality medicines. Thus, a high amount of investments is made to initiate advanced facilities for cryopreservation cell lines. For instance, New York Blood Center’s - National Cord Blood Program (NCBP), is the world's first and largest cord bank, which freezes and preserves cord blood units in liquid nitrogen freezers. It has recorded a collection of over 70,000 cord blood units and provided cord blood units for transplantation to over 5,300 recipients worldwide.
Burgeoning Geriatric Cases – With the weakening of the human body and deteriorating body organs demand high-quality medicine. Thus, with cryopreservation cell lines, effective research methodologies can be carried out for developing efficacious methodologies for treatment processes. The World Health Organization stated that by 2030, one out of six people in the world is bound to age 60 years and over.
Rising Prevalence of Chronic Diseases – Recent statistics from the World Health Organization (WHO) stated that chronic diseases are responsible for almost all the deaths occurring worldwide. Cardiovascular diseases take almost 17.9 million lives annually, followed by cancers, chronic respiratory diseases, and diabetes responsible for killing 9.3 million, 4.1 million, and 2 million people every year across the globe.
Increased Focus on Developing Advanced Medical Procedures – High investments are made by key players operating in the global market in research and development activities to enhance the process of cryopreservation along with the expansion of healthcare expenditure. Thus, robust expenditure in the R&D sector is expected to bring growth opportunities for market expansion in the near future. According to the World Bank, global expenditure on research and development was calculated to be 2.63% of GDP in 2020 up from 2.2% in 2018.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
20.2% |
|
Base Year Market Size (2024) |
USD 13.94 billion |
|
Forecast Year Market Size (2037) |
USD 152.41 billion |
|
Regional Scope |
|
Application (Stem Cells, Oocytes & Embryos, Sperm, Semen, Testicular Tissue, Hepatocytes)
The global cryopreservation cell lines market is segmented and analyzed for demand and supply by application into stem cells, oocytes & embryos, sperm, semen, testicular tissue, hepatocytes, and others. Out of these, the oocytes & embryos segment is estimated to hold the largest share of the market by the end of 2037. The major factor attributed to the segment growth is the rising number of female infertility cases around the globe. As per the data from the Centers for Disease Control and Prevention (CDC), it is revealed that in the United States, 1 out 5 women falling under the age group of 15 to 49 years are unable to get pregnant even after trying for one year. Cryopreservation cell lines are effective in preserving the eggs, oocytes, and embryos in in-vitro fertilization banking services which further helps women to get pregnant. The infertile population is highly reliant on cryopreservation cell lines as it allows them to get pregnant and control the process, making it a highly preferred option. According to the guidelines by the American Society for Reproductive Medicine, it was estimated that the survival rate of frozen oocytes after vitrification is 90%–97%, and the fertilization rate is 71%–79% for frozen eggs.
End-user (Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes)
The global cryopreservation cell lines market is also segmented and analyzed for demand and supply by end-user in hospitals, pharmaceutical & biotechnology companies, research institutes, and others. Out of these, the hospital segment is attributed to holding a significant share with a noteworthy revenue generation. Factors that are anticipated to aid segment growth in the upcoming years are the availability of a wide number of hospitals across every nation of the world along with the rapid escalation of inpatients and outpatient flow in the hospitals. Moreover, the presence of a robust base of hospitals and government support in enhancing hospital infrastructure is considered to be another factor that is anticipated to impetus a strong revenue generation for segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Application |
|
|
By End User |
|
North American Market Forecast
North America industry is estimated to dominate majority revenue share of 42% by 2037. The market in the region is estimated to witness a noteworthy share over the forecast period on the back of increasing healthcare expenditure on research and development activities by pharmaceutical and other biotech companies. For instance, according to World Bank data, current health expenditure (% of GDP) in North America increased from 12.2% in 2000 to 16.32% in 2019, growing at an average annual rate of 1.57%. Further, the increasing focus of market players on developing novel products for preserving various cells for research and use in medical settings is a major factor propelling the market growth in the region. For instance, Merck KGaA invested approximately USD 2.8 billion in 2020 in R&D. The company focused on both in-house research and external collaborations to launch new and innovative products.
APAC Market Statistics
On the other hand, the market in the Asia Pacific region is expected to grow at the highest growth rate during the forecast period due to improved healthcare infrastructure and accelerating product management operations. Optimization of cryopreservation is the rapidly developing segment in this region and is likely to increase the demand for cryopreservation cell lines in Asia Pacific countries.
BioLife Solutions, Inc. invented cryopreservation, thawing, and cold chain transport technologies and also announced three new patents for the same. The company also received a European Patent for its Apparatuses and Compositions for the Cryopreservation of Cellular Monolayers.
Shinshu University, Japan, developed a technology to cryopreserve animal cells without using cryoprotectants by the super flash freezing method. This technology rapidly freezes cells by encapsulating cells in microdroplets with inkjet cell printing technology and discharging them onto a liquid nitrogen-cooled glass substrate.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?